NBNina Borràs

Nina Borràs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nina Borràs has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Resolving structural variants in hemophilia: insights from long-read sequencing and molecular and clinical implications.

    by Nina Borràs Agustí, Iris Garcia-Martínez, Belén de la Morena-Barrio, Laia Closa, Lorena Ramírez, Noemí González, Natàlia Comes, Carina Lera, Elisenda Farssac, Rafael Parra, et al.

    Structural variants (SVs) in F8 and F9 are major causes of severe hemophilia, yet their mechanistic basis and clinical impact remain incompletely understood. We aimed to implement an integrated workflow to define hemophilia-associated SVs at nucleotide resolution and to explore genomic signatures and clinical correlates. We analyzed 25 unrelated families non-recurrent SVs with hemophilia A (HA;n=20) or hemophilia B (HB;n=5) using genome walking, short-read sequencing, and nanopore whole-genome long-read sequencing (WGS-LRS). In HA, we resolved 15 partial F8 deletions (from 249 bp to ~0.5 Mb), one tandem duplication, and four complex rearrangements. In HB, we characterized three large F9 deletions (including one partial and two whole-gene deletions, up to >4 Mb) and two pathogenic exonic Alu insertions. In four cases, MLPA calls were incomplete or misleading, whereas WGS-LRS uncovered breakpoints and structures missed by standard workflows. Notably, repetitive elements were present at least one breakpoint in nearly all SVs (22/25), implicating local genomic architecture in SV formation. Breakpoint-junction analysis revealed short microhomologies in most events (F8: 18/20; F9: 3/5), supporting microhomology-mediated end joining or replication-based mechanisms as predominant pathways. WGS-LRS enabled methylation-based assessment of skewed X-inactivation in a carrier with a Xq28 deletion. Inhibitors were reported in 4/16 and 3/4 evaluable HA and HB cases, respectively. Overall, this study provides the first systematic application of nanopore WGS-LRS as a transformative genomic diagnostic approach for comprehensive SV analysis in hemophilia, enabling definitive SV delineation, correcting misclassification by conventional testing, and supporting mechanism-informed interpretation to improve molecular diagnosis and genetic counseling.

  • Open Access

    Co‐inheritance of ITGA2B and TUBB1 variants in a family reveals distinct genetic contributions to platelet dysfunction

    by Perla Bandini, Nina Borràs, Laura Martin‐Fernandez, Nuria Fernández‐Mosteirín, Maria Reyes Aguinaco, Olga Benítez, Natàlia Comes, Lorena Ramírez, Noemí González, Carina Lera, et al.


  • Open Access

    Integrating Next‐Generation Sequencing Into Routine Molecular Diagnosis of Inherited Coagulation Factor Deficiencies: Real‐World Data From Spanish Patients

    by Nina Borràs, Natàlia Comes, Lorena Ramírez, Rafael Parra, Carmen Altisent, Álvaro Lorenzo‐Vizcaya, Cristina Marzo‐Alonso, Maria‐Fernanda López‐Fernández, Mariana Canaro, María Falcón‐Rodríguez, et al.

    Introduction: Inherited coagulation factor deficiencies (ICFD) result from plasma protein deficiencies, impacting blood coagulation cascade and leading to haemorrhagic diathesis. Advancements in next‐generation sequencing (NGS) technology have enabled high‐throughput methods for molecular ICFD diagnosis. However, detailed descriptions of clinical applications and routine laboratory experiences in this field remain scarce. Aim: This study presents the results from a real‐world experience using an NGS‐based gene panel for routine molecular diagnosis, applied to more than 500 ICFD patients in Spain. Methods: A custom NGS gene panel targeting 22 ICFD‐related genes was validated using 20 patients with known variants. Subsequently, the panel was applied to 515 ICFD patients from 28 Spanish hospitals. Structural variants were detected by multiplex ligation‐dependent probe amplification. Results: Among the 515 patients analysed, 402 had complete phenotypic data specified in the genetic study form, 83 had incomplete data, and 30 were potential haemophilia carriers. Identification disease‐causing variant rates were 69%, 58% and 53%, respectively. Candidate variants were identified in 74% of cases. A total of 460 variants across 18 genes were identified, 302 unique variants, with 37% being novel disease‐causing variants. Conclusion: This study represents the largest analysis of ICFD patients conducted in Spain, providing significant insights into the molecular epidemiology of these disorders. It underscores the critical role of NGS in routine clinical practice while addressing challenges faced by genetic laboratories. The findings highlight a growing shift among haematologists towards integrating genetic studies early in diagnostic workflows alongside phenotypic assessments to enhance the accuracy and efficiency of ICFD diagnosis.


  • First description of bone marrow failure syndrome in Spain caused by mutations in the ERCC6L2 gene

    by Perla Bandini, Nina Borràs, Eugenia Fernandez Mellid, Laura Martin‐Fernandez, Paula Melero Valentín, Natalia Comes, Lorena Ramírez, Patricia Cadahia Fernández, Matilde Rodríguez Ruiz, Manuel Mateo Perez Encinas, et al.


  • Molecular study of a large cohort of 109 haemophilia patients from Cuba using a gene panel with next generation sequencing‐based technology

    by Nina Borràs, Dunia Castillo‐González, Natalia Comes, Laura Martin‐Fernandez, René Antonio Rivero‐Jiménez, Arturo Chang‐Monteagudo, Vera Ruiz‐Moleón, Heidys Garrote‐Santana, Francisco Vidal, Consuelo Macías‐Abraham

    Introduction: In several countries, molecular diagnosis of haemophilia A (HA) and B (HB) is hampered by a lack of resources for DNA analysis. The advent of next‐generation sequencing (NGS) has enabled gene analysis at a reasonable cost.Aim: Describe a collaboration between Cuban and Spanish researchers to identify candidate variants and investigate the molecular epidemiology of 106 Cuban haemophilia patients using NGS.Patients/methods: The molecular analysis protocol included well‐established LR‐PCR procedures to detect F8 inversions, NGS with a 30‐gene panel to sequence F8 and F9, and multiplex ligation‐dependent probe amplification to identify large structural variants.Results: One‐hundred and thirty‐one candidate variants were identified along F8, F9, and VWF; 72 were unique and 28 (39%) had not been previously recorded. Putative variants were identified in 105/106 patients. Molecular characterization enabled confirmation and reclassification of: 90 HA (85%), 15 HB (14%), and one type 2N VWD (1%). Null variants leading to non‐production of FVIII or FIX were common in severe HA (64%), moderate HA (74%), and severe HB (60%), whereas missense variants were frequent in mild HA (57%) and moderate or mild HB (83%). Additional variants in VWF were identified in 16 patients.Conclusion: This is the first description of the molecular epidemiology of HA and HB in Cuba. Variants identified in index cases will be of value for local implementation of familial studies and prenatal diagnosis using the molecular approaches available in Cuba. The results of this protocolled genetic study improved the accuracy of the clinical diagnosis and will facilitate management of these patients.


  • Type 2N VWD: Conclusions from the Spanish PCM‐EVW‐ES project

    by Almudena Pérez‐Rodríguez, Javier Batlle, Joana Costa Pinto, Irene Corrales, Nina Borràs, Iris Garcia‐Martínez, Ana Rosa Cid, Santiago Bonanad, Rafael Parra, María Eva Mingot‐Castellano, et al.

    Introduction: Type 2N von Willebrand disease (VWD) is characterized by a decreased affinity of von Willebrand factor (VWF) for factor VIII (FVIII). Abnormal binding of FVIII to VWF (VWF:FVIIIB), results in low FVIII plasma levels, which can lead to a misdiagnosis of mild haemophilia A. Accurate diagnosis of type 2N VWD is essential for appropriate genetic counselling and therapy. This disease can be distinguished from haemophilia A by in vitro assays (measurement VWF:FVIIIB activity) and/or genetic analysis.Aim: To identify the current challenges in the diagnosis and treatment of this type of VWD and provide an in‐depth description of the phenotypes and mutations identified.Results: Twenty‐eight patients had at least one type 2N mutation, and 13 of these had a type 2N mutation combined with other variations. Three type 2N mutations were detected: p.Arg816Trp, p.Arg854Gln, and p.Arg763Ser. Two of these are the most frequently described mutations worldwide. This mutational spectrum differs from the broad spectrum seen in neighbouring France, where at least eight distinct 2N mutations have been found. In the PCM‐EVW‐ES cohort, 11 asymptomatic type 2N carriers with borderline FVIII plasma levels would probably have been excluded if the evaluation had been based on clinical and laboratory data only. Likewise, three patients with a severe phenotype would have been classified as homozygous for a 2N mutation if only the phenotype study had been performed.Conclusion: The high detection yield and affordability of next‐generation sequencing support the use of this technology as a first‐line diagnostic tool in this setting.